Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin-Reference-Cited by-同舟云学术

Pharmacokinetic Characterization of Amrubicin Cardiac Safety in an Ex Vivo Human Myocardial Strip Model. I. Amrubicin Accumulates to a Lower Level than Doxorubicin or Epirubicin

Published:2012-02-15 Issue:2 Volume:341 Page:464-473
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Salvatorelli Emanuela,Menna Pierantonio,Surapaneni Sekhar,Aukerman Sharon L.,Chello Massimo,Covino Elvio,Sung Victoria,Minotti Giorgio

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference43 articles.

1. The GOA database in 2009--an integrated Gene Ontology Annotation resource

2. Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs

3. Phase II Study of Amrubicin As Second-Line Therapy in Patients With Platinum-Refractory Small-Cell Lung Cancer

4. Ewer MS Benjamin RS (2006) Doxorubicin cardiotoxicity: Clinical aspects, recognition, monitoring, treatment, and prevention, in Cancer and the Heart ( Ewer MS Yeh E , eds) pp 9–32, BC Decker, Hamilton, Ontario, Canada.

5. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Phase II trial of single agent amrubicin in patients with previously treated advanced thymic malignancies;Lung Cancer;2019-11

2. Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity;Current Medicinal Chemistry;2017-06-30

3. Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin;Journal of Pharmacology and Experimental Therapeutics;2017-05-30

4. The concomitant management of cancer therapy and cardiac therapy;Biochimica et Biophysica Acta (BBA) - Biomembranes;2015-10

5. Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial;Breast Cancer Research and Treatment;2014-11-06